The strongest Wegovy alternatives in 2026 are Zepbound (more potent, often cheaper), Foundayo (oral pill at $149/month), Mounjaro (cheapest if you have type 2 diabetes), and compounded semaglutide or tirzepatide (legitimate when prescribed correctly). Which one is right depends on your insurance, your diagnosis, and how much weight you have to lose.
Here's the head-to-head breakdown for every legitimate Wegovy alternative — what it costs, how it compares clinically, and which type of patient each one fits.
Why look for a Wegovy alternative?
Five common reasons our readers switch in 2026:
- Cost. Wegovy lists at $1,349/month; NovoCare direct-pay is $499/month. Several alternatives are cheaper.
- Stronger weight loss. Zepbound (tirzepatide) produces ~20% mean body-weight loss in head-to-head trials vs ~14% on Wegovy. If you've plateaued or have more weight to lose, the more-potent option matters.
- Insurance dropped Wegovy. Roughly 24 million Americans lost commercial GLP-1 coverage in 2025–2026 — BCBS Massachusetts, Harvard Pilgrim, and several other plans restricted Wegovy specifically. See our coverage update.
- Side effects. Wegovy nausea rates (~44% in trials) run higher than tirzepatide alternatives (~33%). Patients hitting intolerable GI symptoms often switch.
- Injection format. Daily oral pills (Foundayo, oral Wegovy) are now available at $149/month if injection is a dealbreaker.
Zepbound (tirzepatide) — the most potent alternative
Zepbound is the same molecule as Mounjaro (tirzepatide), labeled for chronic weight management. It's Eli Lilly's direct competitor to Wegovy and the strongest clinically.
Key facts:
- Average weight loss: ~20% body weight at 72 weeks (vs ~14% for Wegovy)
- Cost (list): $1,089/month for the auto-injector pen
- Self-pay (LillyDirect vials): $349–$549/month
- Foundayo (oral tirzepatide pill): $149/month
- Mechanism: Dual GIP/GLP-1 receptor agonist (Wegovy is GLP-1 only)
- Side effects: Lower nausea rate than Wegovy in pivotal trials
Who should pick it: Patients with more weight to lose, patients who've plateaued on max-dose Wegovy, or patients whose insurance covers Zepbound but not Wegovy.
Full head-to-head: See our Zepbound vs Wegovy 2026 comparison.
Foundayo (oral tirzepatide) — the cheapest legitimate brand
Foundayo is the oral pill version of tirzepatide, FDA-approved April 2026 and shipping via LillyDirect. It's the cheapest brand-name path to a tirzepatide-quality drug in 2026.
Key facts:
- Average weight loss: ~12–15% body weight at highest dose (Phase 3 trial data) — slightly less than injectable Zepbound but still substantial
- Cost: $149/month via LillyDirect (any dose)
- Format: Daily oral pill taken with food
- Side effects: Similar to injectable tirzepatide, GI-dominant
- Access: Direct order via LillyDirect, no pharmacy visit needed
Who should pick it: Cost-sensitive patients, patients who want to avoid injections, patients who want the lowest legitimate brand price. Probably the single biggest 2026 Wegovy alternative.
How to order: See our Foundayo step-by-step guide.
Mounjaro (tirzepatide for diabetes) — cheapest if you have T2D
Mounjaro is chemically identical to Zepbound — same molecule, same manufacturer, different FDA label. It's approved for type 2 diabetes only, which means insurance covers it differently.
Key facts:
- Average weight loss: Identical to Zepbound at the same dose (same drug)
- Cost (list): $1,069/month
- With insurance + Mounjaro Savings Card: as low as $25/month for commercially insured T2D patients
- Eligibility: Requires confirmed type 2 diabetes diagnosis (HbA1c ≥6.5%)
- Mechanism: Dual GIP/GLP-1, identical to Zepbound
Who should pick it: Patients with both type 2 diabetes and obesity. This is the cheapest path to tirzepatide-quality weight loss for anyone who qualifies.
Eligibility details: See our Mounjaro $25 savings card guide and our Zepbound = Mounjaro identity guide.
Oral Wegovy (semaglutide pill) — same molecule, pill format
Oral Wegovy is the same semaglutide as injectable Wegovy, available as a daily pill. Launched January 2026 via NovoCare.
Key facts:
- Average weight loss: ~13% body weight at highest dose
- Cost: $149/month at the lowest dose via NovoCare direct-pay
- Format: Daily oral pill taken on an empty stomach (must fast 30 minutes after)
- Side effects: Similar profile to injectable Wegovy
Who should pick it: Patients who tolerated Wegovy well and want the pill format at lower cost, or first-time users who want a low-commitment entry point.
3-month patient experience: See our oral Wegovy review.
Compounded semaglutide — cheapest path overall
Compounded semaglutide is made by 503A/503B compounding pharmacies in dose-flexible vials. It's the same active ingredient as Wegovy/Ozempic, prepared by a pharmacy rather than purchased pre-filled from Novo Nordisk.
Key facts:
- Average weight loss: Equivalent to brand-name Wegovy at matched doses
- Cost: $99–$299/month depending on provider
- Format: Weekly subcutaneous injection, vial + syringe
- Risks: FDA enforcement has tightened since the shortage resolved in late 2024. Quality varies — use LegitScript-certified providers only.
Who should pick it: Cash-pay patients seeking the lowest legitimate price, patients who want dose flexibility (maintenance microdosing, gradual titration), patients in regions where brand-name Wegovy isn't accessible.
Providers we recommend for compounded semaglutide:
- Eden Health — Board-certified physicians, comprehensive baseline labs, named-MD oversight.
- TrimRx — Personalized doctor consultations, dose flexibility built in.
- Yucca Health — LegitScript-certified, BNPL financing, named physicians.
- ShedRx — Compounded options with transparent pricing.
For the full ranking of compounded GLP-1 providers, see our best GLP-1 telehealth programs list.
Compounded tirzepatide — strongest cash-pay option
Compounded tirzepatide is the same molecule as Zepbound/Mounjaro, dispensed by compounding pharmacies.
Key facts:
- Average weight loss: Equivalent to brand-name Zepbound at matched doses (~20% body weight)
- Cost: $199–$399/month depending on provider
- Status: FDA enforcement targeted the unsafe end of the market in 2025–2026. Legal when prescribed for medical necessity through 503A/503B pharmacies.
Who should pick it: Cash-pay patients who want maximum weight loss without paying Lilly's brand prices. Watch quality carefully.
Providers: Same list as compounded semaglutide above — most prescribe both molecules.
Saxenda and Victoza (liraglutide) — older daily GLP-1s
Liraglutide is the first-generation GLP-1 receptor agonist. Saxenda is the weight-loss label, Victoza is the diabetes label.
Key facts:
- Average weight loss: ~5–8% body weight at 56 weeks (less than newer drugs)
- Cost: Saxenda $1,300+/month list, with savings programs that vary
- Format: Daily subcutaneous injection (not weekly)
- When to consider: Almost never, in 2026 — newer drugs are more effective and not significantly more expensive
Who should pick it: Patients whose insurance specifically covers Saxenda/Victoza but not the newer drugs. Otherwise, this is the previous-generation option.
Non-GLP-1 alternatives (mostly last resort)
If GLP-1s aren't accessible to you for cost or medical reasons, the older weight-loss drugs:
- Phentermine (Adipex): Stimulant appetite suppressant. $10–$30/month generic. Weight loss ~3–5%. Approved for short-term use (3 months) — not a chronic option.
- Phentermine + topiramate (Qsymia): Combination drug. ~7–8% weight loss. $80–$150/month. Side effects include cognitive slowing.
- Naltrexone + bupropion (Contrave): Different mechanism, ~5–6% weight loss. $80–$150/month.
- Orlistat (Xenical/Alli): Fat-absorption blocker. ~3% weight loss. Significant GI side effects. Available OTC at lower dose.
Who should pick these: Patients with absolute contraindications to GLP-1s, or patients whose insurance won't cover GLP-1s and can't afford cash-pay options.
Cost comparison — Wegovy vs alternatives in 2026
Cheapest legitimate paths, in order:
- Compounded semaglutide: $99/month (varies)
- Foundayo oral tirzepatide: $149/month via LillyDirect
- Oral Wegovy: $149/month at lowest dose via NovoCare
- Mounjaro with Savings Card + insurance: $25/month (T2D only)
- Compounded tirzepatide: $199/month (varies)
- Zepbound LillyDirect vials: $349–$549/month
- Wegovy NovoCare cash: $499/month
- Brand Wegovy list: $1,349/month
For our complete pricing analysis with state-by-state insurance data, see our GLP-1 price war breakdown.
How to switch from Wegovy to an alternative
Three rules for a smooth switch:
- Don't stop cold turkey. Schedule your last Wegovy injection so it aligns with starting the alternative — typically your last Wegovy dose covers you for the first week of the new drug.
- Restart the titration ladder. Even if you were on max-dose Wegovy, the alternative drug starts at its own lowest dose. Don't try to convert mg-for-mg — the dose equivalencies are not 1:1.
- Tell your provider what you're switching from. Important for monitoring side effects (you may have residual semaglutide in your system for 2–3 weeks after your last Wegovy injection).
If you're switching for cost reasons, our stop-restart muscle loss analysis covers what to watch during the transition.
Frequently asked questions
What's the best Wegovy alternative for weight loss? Zepbound (tirzepatide). More potent (~20% weight loss vs ~14% for Wegovy), generally better tolerated, available cheaper through LillyDirect vials. See our head-to-head comparison.
What's the cheapest Wegovy alternative? Compounded semaglutide at $99/month from select providers, or Foundayo at $149/month if you want a brand-name path. Both are legitimate options when prescribed correctly.
Can I switch from Wegovy to a compounded version? Yes, with a prescriber's involvement. Many telehealth providers can write a compounded semaglutide prescription as a direct substitute. Quality matters — see our provider screening list above.
Is Zepbound considered a Wegovy alternative? Yes, in clinical practice. They're competing drugs for the same indication (chronic weight management), made by competing manufacturers (Lilly vs Novo). Many patients try one, switch to the other.
What about retatrutide, the next-generation drug? Retatrutide (Lilly's triple agonist) is in Phase 3 trials with FDA decision likely in 2027. Phase 2 data showed up to 24% body-weight loss. Not yet a legitimate alternative — wait for approval.
Can I get any GLP-1 alternative covered by Medicare? CMS's new GLP-1 Bridge program launches July 1, 2026, capping copays for Wegovy, Zepbound, and Foundayo at roughly $50/month for Part D enrollees who meet criteria. See our Medicare GLP-1 Bridge Program guide.
Bottom line
In 2026, the strongest Wegovy alternatives by patient profile:
- Want more weight loss? → Zepbound or compounded tirzepatide.
- Cost-sensitive? → Foundayo ($149) or compounded semaglutide ($99–$199).
- Have type 2 diabetes? → Mounjaro with Savings Card ($25/month).
- Need a pill instead of injection? → Foundayo or oral Wegovy (both $149).
- Insurance dropped Wegovy? → Check formulary for Zepbound; if not covered, LillyDirect vials.
- GLP-1s contraindicated? → Phentermine, Qsymia, or Contrave — but expect smaller weight loss.
The most important practical decision isn't which alternative you pick — it's which provider you pick. The same molecule with a good prescriber (slow titration, baseline labs, nutritional counseling, dose flexibility) produces dramatically different outcomes than the same molecule with a fast-prescribing fixed-protocol clinic. See our top-rated GLP-1 telehealth programs for the shortlist we'd send a friend.